The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Didronel
Synonyms :
etidronate
Class :
Calcium Metabolism Modifiers
Brand Name :
Didronel
Synonyms :
etidronate
Class :
Calcium Metabolism Modifiers
Dosage Forms & Strengths Â
Tablet Â
200mg Â
400mg Â
5 - 10
mg/kg
Orally 
every day
and do not exceed 6 months
do not exceed 20 mg/kg/day
Total hip replacement :
20
mg/kg
Orally 
every day
1
month
before and 3 months post-surgery for 4 months
Spinal cord injury
Total 12 weeks dose: 20 mg/kg orally every day for 2 weeks, following 10 mg/kg every day for10 weeks
It may decrease the effects of human parathyroid hormone
may diminish the serum concentration of polyvalent cation-containing products
may increase the risk or severity of methemoglobinemia when miltefosine is combined
may diminish the serum concentration of Polyvalent Cation Containing Products
aluminum hydroxide/magnesium carbonateÂ
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may diminish the serum concentration of polyvalent cation-containing products
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
may have an increasingly adverse effect when combined with bisphosphonate derivatives
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
may increase the hypo calcaemic effect
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of angiogenesis inhibitors
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
neomycin/polymyxin B/bacitracin topical
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
It may increase the nephrotoxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may enhance the risk of adverse effects when combined with Phosphodiesterase inhibitors
may have an increasingly adverse effect when combined with bisphosphonate derivatives
the risk of anti-angiogenesis and jaw osteonecrosis may be increased
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
may have an increasingly adverse effect when combined with bisphosphonate derivatives
Adverse drug reactions Â
Frequency Defined Â
1-10% Â
Hypocalcemia Â
Hypomagnesemia Â
Convulsion Â
Abnormal renal function Â
Fever Â
Bone pain Â
Hypophosphatemia Â
Frequency Not Defined Â
Hallucination Â
Headache Â
Amnesia Â
Depression Â
Confusion Â
Pregnancy warnings:   
AU TGA pregnancy category: CÂ
Lactation: Â
Excreted into human milk is unknown Â
Pregnancy Categories:       Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category Â
Patient Information Leaflet   Â
Generic Name: etidronateÂ
Why do we use etidronate? Â
etidronate is an Calcium Metabolism Modifiers used to treat Paget Disease and Heterotopic Ossification.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
